CULVER CITY, Calif. & BOSTON--(BUSINESS WIRE)--Cancer MoonShot 2020:
WHAT: Press Conference with Patrick Soon-Shiong, MD, CEO of NantWorks and Founder of Cancer MoonShot 2020, and a panel that includes premier oncologists and researchers, biotech and leaders from community oncologists New England Cancer Specialists as well as other renowned experts. The panel will present clinical results of novel neoepitope antibody trials to date and how this multidisciplinary collaborative can help rapidly advance the promise of personalized cancer vaccines for more patients.
ANNOUNCEMENT:
The collaboration with prominent Maine-based community oncologists New England Cancer Specialists (NECS) represents the first personalized immuno-oncology supercomputing collaboration to implement and support the Centers for Medicare & Medicaid Services’ (CMS) new Oncology Care Model (OCM) with patient and provider centric technology and administrative support to provide higher quality, better coordinated oncology in local communities and to ensure that 21st century treatments are deployed by local community oncologists.
With successful completion of Phase II clinical trials of novel neoepitope antibodies, clinical scientists from major academic centers and collaborators under CRADA agreements with NCI will share findings and discuss plans to leverage learnings to advance treatments for women’s cancers, such as ovarian, as well as cancers affecting children.
DISCUSSION POINTS:
Together, they will discuss how advanced molecular science and leading-edge technology are rapidly advancing immunotherapy as the next generation of cancer care. Additionally, they will discuss a unique collaboration with NECS who champion equitable access to the most advanced cancer care possible to patients within their own community. Among the key insights to be shared by Dr. Soon-Shiong and his panelists are:
- Advancements in immunotherapy enabled by artificial intelligence and advanced molecular science to provide oncologists with unprecedented insights to help identify personalized, cost-effective therapy strategies before treatment begins.
- The development and understanding of novel neoepitope antibodies, and their role in finally achieving low toxicity, targeted cancer therapy—with the ultimate hope of accelerating FDA approvals of effective and safe cancer antibodies or vaccines.
- The role of machine learning in the complex understanding of the cancer genome and how the Supercomputing Medical Reasoning Engine provides real-time predictive modeling and clinical outcomes that can continually improve physicians’ ability to make more effective care decisions.
- How NECS and participating oncologists will leverage the Supercomputing Infrastructure and a suite of cutting-edge technology to meet OCM’s new targets for better care, smarter spending and healthier populations as well as accessing 21st century immuno-oncology clinical trials.
- The use of the Supercomputing Genomics Engine to establish the world’s largest knowledge base of genomic and proteomic profile of brain tumors from children - The Brain Tumor Atlas.
WHO:
1. Patrick Soon-Shiong, MD, Founder and CEO, NantWorks, leader of the Cancer MoonShot 2020 program
2. Philip M. Arlen, MD, CEO and Chief Medical Officer, Precision Biologics, Inc. and Attending Physician at the Walter Reed Military Medical Center and Medical Oncology Branch of the National Cancer Institute
3. Carla Balch, President, NantCare
4. Leonard Sender, MD, Executive Director Pediatric, Adolescent and Young Adult Cancer Moonshot 2020
5. Richard D. Kim, MD, Associate Professor, Department of Gastrointestinal Oncology and Medical Director, H. Lee Moffitt Cancer Center
6. Adam C. Resnick, PhD, Research Scientist, Department of Biomedical and Health Informatics at The Children’s Hospital of Philadelphia
7. Giannoula Lakka Klement, MD, Chief, Academic and Research Affairs, Division of Pediatric Hematology/Oncology, Director, Rare Tumors & Vascular Anomalies Program; Assistant Professor, Tufts University School of Medicine
8. Christian A. Thomas, MD, Director of Clinical Research, New England Cancer Specialists
9. Tracey F. Weisberg, MD, President and Lead Physician, New England Cancer Specialists
| WHEN: | Wednesday, October 26, 11:00 a.m. – 1:30 p.m. ET | ||
| WHERE: | Hyatt Regency – Boston, Nantucket Room | ||
| 1 Ave de Lafayette | |||
| Boston, MA 02111 | |||
| CONTACT: | Dorit Baxter | ||
| NantHealth | |||
| 401-871-0734 | |||
| All Media Must RSVP and Be Credentialed to Attend | |||
| Photos from the event will be available on www.gettyimages.com | |||
For more information on Dr. Patrick Soon-Shiong, Cancer MoonShot 2020 and QUILT, please visit:
http://www.nature.com/nature/journal/v537/n7619_supp/full/537S63a.html
http://jamanetwork.com/journals/jama/article-abstract/2551878
http://www.cbsnews.com/news/billionaire-doctor-fights-cancer-in-unconventional-way/
About NantWorks
NantWorks, LLC, founded by renowned physician scientist and inventor of the first human nanoparticle chemotherapeutic agent Abraxane®, Dr. Patrick Soon-Shiong, is the umbrella organization for the following entities: NantHealth, NantMobileHealth, NantOmics, NantBio, NantCell, NantPharma, NantCapital and NantCloud. Fact-based and solution-driven, each of NantWorks’ division entities operates at the nexus of innovation and infrastructure. The core mission of NantWorks is convergence and a systems approach to human biology: to develop and deliver a diverse range of technologies that accelerates innovation, broaden the scope of scientific discovery, enhance ground-breaking research, and improve healthcare treatment for those in need. NantWorks is building an integrated fact-based, genomically and proteomically -informed, personalized approach to the delivery of care and the development of next generation diagnostics and therapeutics for life threatening diseases such as Cancer, Infectious Diseases and Alzheimer’s. For more information please visit www.nantworks.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About Cancer MoonShot 2020
The Cancer MoonShot 2020 program is one of the most comprehensive cancer collaborative initiative launched to date, seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational moonshot to develop an effective vaccine-based immunotherapy to combat cancer by 2020. For more information, please visit www.cancermoonshot2020.org and follow @MoonShot2020 on Twitter.
About NantCare
NantCare, a member of the NantWorks ecosystem of companies, is committed to ensuring every cancer patient has access to true immunotherapy clinical trials (QUILT) or optimized treatment based on GPS Cancer Scan results. By organizing all relevant data and making it available for the world, NantCare aims to spread oncology-related intelligence to maximize support of patients, physicians and life science companies. NantCare embraces life science company partnerships and strives to developing treatments guided by genomic, transcriptomic and quantitative proteomic data. By supporting community oncology clinically and financially, NantCare is ensuring they continue to serve the majority of cancer patients in the US.
NantHealth
Dorit Baxter, 401-871-0734
